Robert A. Beardsley - 18 Mar 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director
Signature
/s/ David C. Hastings as attorney-in-fact for Robert Alan Beardsley
Issuer symbol
ABUS
Transactions as of
18 Mar 2025
Net transactions value
$0
Form type
4
Filing time
20 Mar 2025, 16:10:16 UTC
Previous filing
06 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +157,600 $0.000000 157,600 18 Mar 2025 Common Shares 157,600 $3.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2 This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date.